Simon Harris (Wicklow, Fine Gael) | Oireachtas source

Yes. I am very much aware of this case. It is a matter for the HSE to follow its own reimbursement processes legally in this respect. I met the HSE on a number of issues recently and this was one issue that I raised specifically. It is important that there is real and meaningful engagement with the drugs company and with the HSE. The technology review group on rare diseases is currently working its way through the application. It will go to the HSE leadership shortly for decision also. I acknowledge it is an issue of significant concern to a number of parents in the State. It is currently with the technology review group on rare diseases and it will go from there to the HSE leadership team.